Reviewing Corcept Therapeutics Incorporated (CORT)’s and BioTime Inc. (NYSEAMERICAN:BTX)’s results

This is therefore a contrasting of the risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership in Corcept Therapeutics Incorporated (NASDAQ:CORT) and BioTime Inc. (NYSEAMERICAN:BTX). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corcept Therapeutics Incorporated 237.70M 5.61 151.73M 1.45 8.96
BioTime Inc. 5.23M 28.21 72.97M -0.58 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 represents Corcept Therapeutics Incorporated (NASDAQ:CORT) and BioTime Inc. (NYSEAMERICAN:BTX)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Corcept Therapeutics Incorporated 63.83% 66.8% 58.5%
BioTime Inc. -1,395.22% -54.6% -51%

Volatility and Risk

Corcept Therapeutics Incorporated is 63.00% more volatile than Standard & Poor’s 500 because the company has a beta of 1.63. In other hand, BioTime Inc. has beta of 2.21 which is 121.00% more volatile than Standard & Poor’s 500.


Corcept Therapeutics Incorporated’s Current Ratio and Quick Ratio are 5.6 and 5.4 respectively. The Current Ratio and Quick Ratio of its competitor BioTime Inc. are 8.2 and 8.2 respectively. BioTime Inc. therefore has a better chance of paying off short and long-term obligations compared to Corcept Therapeutics Incorporated.

Analyst Ratings

Corcept Therapeutics Incorporated and BioTime Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Corcept Therapeutics Incorporated 0 1 0 2.00
BioTime Inc. 0 0 0 0.00

Corcept Therapeutics Incorporated’s upside potential currently stands at 21.21% and an $14 average target price.

Insider & Institutional Ownership

Roughly 79.5% of Corcept Therapeutics Incorporated shares are owned by institutional investors while 44% of BioTime Inc. are owned by institutional investors. Corcept Therapeutics Incorporated’s share owned by insiders are 0.9%. Competitively, insiders own roughly 5.3% of BioTime Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Corcept Therapeutics Incorporated -6.82% -6.28% -10.36% -30.66% -21.43% -28.13%
BioTime Inc. -9.09% -18.3% -27.6% -25.08% -29.39% -20.2%

For the past year Corcept Therapeutics Incorporated’s stock price has bigger decline than BioTime Inc.


Corcept Therapeutics Incorporated beats BioTime Inc. on 9 of the 12 factors.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with CushingÂ’s syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.